Indaptus Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.09 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 474.57M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and ...